The FDA's approval for Tiziana Life Sciences to expand its patient enrollment significantly increases the potential for the company to validate the efficacy and safety of its Intranasal Foralumab treatment for Multiple Sclerosis. This regulatory milestone is likely to be viewed positively by investors, as it not only demonstrates progress in the company's research and development efforts but also enhances its credibility and potential market opportunity for its treatment. The expansion from 10 to 30 patients allows for more comprehensive data collection, which is crucial for future studies and potential commercialization.